Relax, Cool Down and Scaffold: How to Restore Surface Expression of Folding-Deficient Mutant GPCRs and SLC6 Transporters

H.M. Mazhar Asjad, Shahrooz Nasrollahi-Shirazi, Sonja Sucic, Michael Freissmuth * and Christian Nanoff

Institute of Pharmacology and the Gaston H. Glock Research Laboratories for Exploratory Drug Development, Center of Physiology and Pharmacology, Medical University of Vienna, A-1090 Vienna, Austria; n1442638@students.meduniwien.ac.at (H.M.A.); shahrooz.nasrollahishirazi@meduniwien.ac.at (S.N.-S.); sonja.sucic@meduniwien.ac.at (S.S.); christian.nanoff@meduniwien.ac.at (C.N.)

* Correspondence: michael.freissmuth@meduniwien.ac.at; Tel.: +43-1-40160-31371

Received: 28 October 2017; Accepted: 12 November 2017; Published: 14 November 2017

Abstract: Many diseases arise from mutations, which impair protein folding. The study of folding-deficient variants of G protein-coupled receptors and solute carrier 6 (SLC6) transporters has shed light on the folding trajectory, how it is monitored and how misfolding can be remedied. Reducing the temperature lowers the energy barrier between folding intermediates and thereby eliminates stalling along the folding trajectory. For obvious reasons, cooling down is not a therapeutic option. One approach to rescue misfolded variants is to use membrane-permeable orthosteric ligands. Antagonists of GPCRs are—in many instances—effective pharmacochaperones: they restore cell surface expression provided that they enter cells and bind to folding intermediates. Pharmacochaperoning of SLC6 transporters is less readily achieved because the ionic conditions in the endoplasmic reticulum (ER) are not conducive to binding of typical inhibitors. The second approach is to target the heat-shock protein (HSP) relay, which monitors the folding trajectory on the cytosolic side. Importantly, orthosteric ligands and HSP-inhibitors are not mutually exclusive. In fact, pharmacochaperones and HSP-inhibitors can act in an additive or synergistic manner. This was exemplified by rescuing disease-causing, folding-deficient variants of the human dopamine transporters with the HSP70 inhibitor pifithrin-µ and the pharmacochaperone noribogaine in Drosophila melanogaster.

Keywords: G protein coupled receptors/GPCRs; solute carrier 6/SLC6; misfolding; heat-shock protein relay; pharmacochaperoning; heat-shock protein inhibitors

1. Introduction

Pharmacological chaperoning or pharmacochaperoning refers to the ability of small molecules to increase the expression of their target protein by enhancing productive folding [1,2]. Several pharmacochaperones have recently been approved for clinical use; prominent examples include migalastat and lumacaftor, which restore folding of some mutants of lysosomal α-galactosidase in Fabry’s disease [3] and of CFTR-ΔF508, the most frequently mutated variant of the cystic fibrosis transmembrane conductance regulator (CFTR/ABC-C7) [4]. It has, however, been known for some 40 years that antagonists can enhance the expression of their cognate receptors. This was originally observed in people who had been treated with the β-adrenergic antagonist propranolol: sudden cessation of β-adrenergic receptor blockade resulted in a pronounced increase in angina pectoris attacks and in frequent myocardial infarctions [5,6]. It was subsequently appreciated that this “propranolol withdrawal rebound” was accounted for by elevated β-adrenergic receptor levels at the cell surface in both people [7] and experimental animals [8]. Originally, it was thought that these increase
surface levels reflected a reduced internalization rate of the antagonist-bound β-adrenergic receptors. However, it is now clear that the antagonists act in the endoplasmic reticulum (ER); three observations support this conclusion: (i) the pharmacochaperoning action is contingent on the cell permeability of the antagonist. Landiolol, which is hydrophilic and poorly enters cells, fails to increase the cell surface levels of β1-adrenergic receptors; in contrast, esmolol and propranolol—two antagonists that readily enter cells—promote cell surface expression of the receptor [9]. The action is specific because the non-selective antagonist exerts its actions on both β1- and β2-receptors, while the action of the β1-selective antagonist is confined to β1-receptors [9]; (ii) The pharmacochaperoning action is dependent on a functional ER export machinery: if the formation of COPII (coat protein complex II) coat is disrupted by siRNA-dependent depletion of the cargo receptors SEC24A-D, both propranolol and esmolol fail to increase receptor levels at the cell surface [9]; (iii) The antagonist-induced export from the ER can also be directly visualised under the microscope: within an hour after antagonist application, the refolded receptor is delivered to and concentrated in the Golgi apparatus [10]. Based on these and related findings, it is safe to conclude that cell-permeable ligands act on their targets within the secretory pathway to increase the rate of their delivery to the cell surface [11].

Sickle cell anemia was the first disease appreciated to result from protein misfolding due to a point mutation (E6V of the globin β-chain). In fact, the term molecular medicine was coined to highlight the paradigm shift that arose from the insights into protein misfolding [12]. Sickle cell anaemia can be considered a highly prevalent monogenic folding disease [13]. In all other instances, individual mutant alleles, which encode a folding-deficient version of a protein, are rare. However, collectively, folding diseases account for a large fraction of monogenic diseases. It is also clear that the currently known number must be an underestimate. G protein-coupled receptors (GPCRs) and solute carriers (SLC) comprise the largest and second largest family of membrane proteins with some 800 and 400 members encoded by the human genome, respectively. Thus, collectively, they account for one-fifth of the roughly 6000 membrane proteins. In folding-deficient mutants of GPCRs, the approach to pharmacochaperoning is—in principle—straightforward: antagonist ligands are predicted to act as pharmacochaperones. This prediction was first verified for misfolded V2-vasopressin receptor mutants, which give rise to diabetes insipidus [14]. Transporters are more challenging (see below). There is a long list of mutations that have been shown to result in misfolding of GPCRs [15]; however, it is clear that this list is not exhaustive, because the number of identified mutants keeps growing. This is also true for transporters of the SLC family. To illustrate the point, we selected those nonsynonymous coding mutations reported in the SLC6 family, which give rise to bona fide misfolded proteins. It is evident from the graphic representation in Figure 1 that the cumulative number of disease-associated, folding-deficient mutant has been continuously increasing over the past two decades. Based on this snapshot, it is safe to posit that disease-associated folding-deficient mutants will be identified in each family of membrane proteins. This is also consistent with a large survey covering 1200 human proteins and 2477 disease-associated missense mutations thereof: at least one-third of these result in a folding deficiency [16].
which give rise to a disease due to folding-deficiency, six and three affect intramembrane glycine residues, respectively [38,39]. The helical bundle of the hydrophobic core fails to bind ligands [40]. This is also true for SLC6 transporters [41–43]. In fact, the C-terminus of the C-terminus, for instance, inactivate the A1-adenosine receptor such that its hydrophobic core fails to bind ligands [40]. This is particularly evident for mutants of the dopamine transporter (DAT/SLC6A3) and of the creatine transporter-1 (CrT1/SLC6A8), which are associated with a syndrome of infantile dystonia/Parkinsonism and intellectual disability/mental retardation, respectively. Of the 17 CrT-1 and the 13 DAT mutants, which give rise to a disease due to folding-deficiency, six and three affect intramembrane glycine residues, respectively [38,39]. The helical bundle of the hydrophobic core must be stabilized to prevent lipids from invading the hydrophobic core. Several lines of evidence suggest that this is achieved by the C-terminus in both GPCRs and SLC6 transporters (Figure 2): serial truncations of the C-terminus, for instance, inactivate the A1-adenosine receptor such that its hydrophobic core fails to bind ligands [40]. This is also true for SLC6 transporters [41–43]. In fact, the C-terminus of

2. The C-Terminus as a Folding Checkpoint

We should like to argue that properties that are shared among polytopic membrane proteins of distinct classes are likely to reflect general principles. Hence, insights gained from studying a limited number of examples from two distinct classes of polytopic membrane proteins are also likely to have repercussions for many other protein families. GPCRs and SLC6 transporters differ substantially in their topology: GPCRs have seven transmembrane-spanning α-helices (TM1 to TM7) resulting in an extracellular N-terminus and an intracellular C-terminus. The hydrophobic core of SLC6 transporters comprises twelve transmembrane-spanning α-helices (TM1 to TM12). Because of the even number of transmembrane segments, the N- and C-termini must be on the same side of the membrane, in this instance on the cytosolic side. Nevertheless, GPCRs and SLC6 transporters face a similar folding problem: their transmembrane segments are cotranslationally inserted into SEC61 translocon channel and are released into the lipid milieu of the ER membrane via a lateral gate as an individual α-helix or pairwise [35]. However, the helices must adopt an annular arrangement. Thus, membrane lipids must be displaced on one side to allow for helix packing. Conversely, on the side exposed to the lipid bilayer, the acyl-side chains of the membrane lipids must be accommodated by the helices. The resulting hydrophobic mismatch imposes an energy barrier during the folding and rearrangement of helices [36]. It is therefore not surprising that disease-associated, folding-deficient mutants of SLC6 transporters fall into two major classes: they either map to the lipid/protein interface or they are likely to affect helix packing by replacing glycine residues with bulkier side chains [37–39]. This is particularly evident for mutants of the dopamine transporter (DAT/SLC6A3) and of the creatine transporter-1 (CrT1/SLC6A8), which are associated with a syndrome of infantile dystonia/Parkinsonism and intellectual disability/mental retardation, respectively. Of the 17 CrT-1 and the 13 DAT mutants, which give rise to a disease due to folding-deficiency, six and three affect intramembrane glycine residues, respectively [38,39]. The helical bundle of the hydrophobic core must be stabilized to prevent lipids from invading the hydrophobic core. Several lines of evidence suggest that this is achieved by the C-terminus in both GPCRs and SLC6 transporters (Figure 2): serial truncations of the C-terminus, for instance, inactivate the A1-adenosine receptor such that its hydrophobic core fails to bind ligands [40]. This is also true for SLC6 transporters [41–43]. In fact, the C-terminus of

Figure 1. Cumulative number of point mutations in the coding sequence of mutations, which result in folding-deficient solute carriers (SLC) transporters. The publications were identified in PubMed (www.ncbi.nlm.nih.gov). The numbers are a conservative estimate: only coding variants were counted, where the experimental evidence indicated a loss of function due to misfolding. Truncations due to premature stop codons were ignored, as were mutations, which resulted in a disrupted binding site for substrate and co-substrate ions. The pertinent references are for the norepinephrine transport (NET/SLC6A2 [17], for the creatine transporter-1 (CT1/SLC6A8 [18–28]), for the glycine transporter-2 (GlyT2/SLC6A5 [29,30]), for the dopamine transporter (DAT/SLC6A3 [31–33]) and for the GABA-transporter-1 (GAT1 [34]).

2. The C-Terminus as a Folding Checkpoint

We should like to argue that properties that are shared among polytopic membrane proteins of distinct classes are likely to reflect general principles. Hence, insights gained from studying a limited number of examples from two distinct classes of polytopic membrane proteins are also likely to have repercussions for many other protein families. GPCRs and SLC6 transporters differ substantially in their topology: GPCRs have seven transmembrane-spanning α-helices (TM1 to TM7) resulting in an extracellular N-terminus and an intracellular C-terminus. The hydrophobic core of SLC6 transporters comprises twelve transmembrane-spanning α-helices (TM1 to TM12). Because of the even number of transmembrane segments, the N- and C-termini must be on the same side of the membrane, in this instance on the cytosolic side. Nevertheless, GPCRs and SLC6 transporters face a similar folding problem: their transmembrane segments are cotranslationally inserted into SEC61 translocon channel and are released into the lipid milieu of the ER membrane via a lateral gate as an individual α-helix or pairwise [35]. However, the helices must adopt an annular arrangement. Thus, membrane lipids must be displaced on one side to allow for helix packing. Conversely, on the side exposed to the lipid bilayer, the acyl-side chains of the membrane lipids must be accommodated by the helices. The resulting hydrophobic mismatch imposes an energy barrier during the folding and rearrangement of helices [36]. It is therefore not surprising that disease-associated, folding-deficient mutants of SLC6 transporters fall into two major classes: they either map to the lipid/protein interface or they are likely to affect helix packing by replacing glycine residues with bulkier side chains [37–39]. This is particularly evident for mutants of the dopamine transporter (DAT/SLC6A3) and of the creatine transporter-1 (CrT1/SLC6A8), which are associated with a syndrome of infantile dystonia/Parkinsonism and intellectual disability/mental retardation, respectively. Of the 17 CrT-1 and the 13 DAT mutants, which give rise to a disease due to folding-deficiency, six and three affect intramembrane glycine residues, respectively [38,39]. The helical bundle of the hydrophobic core must be stabilized to prevent lipids from invading the hydrophobic core. Several lines of evidence suggest that this is achieved by the C-terminus in both GPCRs and SLC6 transporters (Figure 2): serial truncations of the C-terminus, for instance, inactivate the A1-adenosine receptor such that its hydrophobic core fails to bind ligands [40]. This is also true for SLC6 transporters [41–43]. In fact, the C-terminus of

Figure 1. Cumulative number of point mutations in the coding sequence of mutations, which result in folding-deficient solute carriers (SLC) transporters. The publications were identified in PubMed (www.ncbi.nlm.nih.gov). The numbers are a conservative estimate: only coding variants were counted, where the experimental evidence indicated a loss of function due to misfolding. Truncations due to premature stop codons were ignored, as were mutations, which resulted in a disrupted binding site for substrate and co-substrate ions. The pertinent references are for the norepinephrine transport (NET/SLC6A2 [17], for the creatine transporter-1 (CT1/SLC6A8 [18–28]), for the glycine transporter-2 (GlyT2/SLC6A5 [29,30]), for the dopamine transporter (DAT/SLC6A3 [31–33]) and for the GABA-transporter-1 (GAT1 [34]).

2. The C-Terminus as a Folding Checkpoint

We should like to argue that properties that are shared among polytopic membrane proteins of distinct classes are likely to reflect general principles. Hence, insights gained from studying a limited number of examples from two distinct classes of polytopic membrane proteins are also likely to have repercussions for many other protein families. GPCRs and SLC6 transporters differ substantially in their topology: GPCRs have seven transmembrane-spanning α-helices (TM1 to TM7) resulting in an extracellular N-terminus and an intracellular C-terminus. The hydrophobic core of SLC6 transporters comprises twelve transmembrane-spanning α-helices (TM1 to TM12). Because of the even number of transmembrane segments, the N- and C-termini must be on the same side of the membrane, in this instance on the cytosolic side. Nevertheless, GPCRs and SLC6 transporters face a similar folding problem: their transmembrane segments are cotranslationally inserted into SEC61 translocon channel and are released into the lipid milieu of the ER membrane via a lateral gate as an individual α-helix or pairwise [35]. However, the helices must adopt an annular arrangement. Thus, membrane lipids must be displaced on one side to allow for helix packing. Conversely, on the side exposed to the lipid bilayer, the acyl-side chains of the membrane lipids must be accommodated by the helices. The resulting hydrophobic mismatch imposes an energy barrier during the folding and rearrangement of helices [36]. It is therefore not surprising that disease-associated, folding-deficient mutants of SLC6 transporters fall into two major classes: they either map to the lipid/protein interface or they are likely to affect helix packing by replacing glycine residues with bulkier side chains [37–39]. This is particularly evident for mutants of the dopamine transporter (DAT/SLC6A3) and of the creatine transporter-1 (CrT1/SLC6A8), which are associated with a syndrome of infantile dystonia/Parkinsonism and intellectual disability/mental retardation, respectively. Of the 17 CrT-1 and the 13 DAT mutants, which give rise to a disease due to folding-deficiency, six and three affect intramembrane glycine residues, respectively [38,39]. The helical bundle of the hydrophobic core must be stabilized to prevent lipids from invading the hydrophobic core. Several lines of evidence suggest that this is achieved by the C-terminus in both GPCRs and SLC6 transporters (Figure 2): serial truncations of the C-terminus, for instance, inactivate the A1-adenosine receptor such that its hydrophobic core fails to bind ligands [40]. This is also true for SLC6 transporters [41–43]. In fact, the C-terminus of
the serotonin transporter (SERT/SLC6A4) interacts with the first intracellular loop (IL1) via a salt bridge [44]. Molecular dynamics simulations also highlight the role of the C-terminus in driving the progression of GPCRs to the minimum energy conformation; a large drop in free energy is associated with packing of the proximal segment of the C-terminus against a hydrophobic pocket created between TM1 and TM7 [45].

![Dopamine transporter and rhodopsin](https://www.ncbi.nlm.nih.gov)

**Figure 2.** Structures of an SLC transporter (dopamine transporter) and a GPCR (rhodopsin) highlighting the circular arrangement of the helices in hydrophobic core. In spite of the truncations of the N- and C-terminal peptide segments, the structures indicate that juxtamembrane N- and C-terminal portions (highlighted in yellow) meet. In the transporter, the structure suggests an end-to-end contact of the cytoplasmic segments. In the receptor, helix 8 of the cytoplasmic carboxyterminus approaches α-helix 1/cytoplasmic loop 1 (IL1). Either arrangement likely serves as latch to stabilize the circular structure. It is also evident that several helices do not run perpendicular to the plane of the membrane; tilting is a reflection of the hydrophobic mismatch, which imposes an energy barrier during the conformational search associated with folding. View from an intracellular (cytosolic) perspective of the tilted dopamine transporter. Extracellular and lateral view of rhodopsin. Structure models (dopamine transporter 4XP4; rhodopsin 2I36) taken from [www.ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov).

Folding of membrane proteins in the ER is assisted by an array of luminal chaperones; for GPCRs, the folding trajectory is monitored by general (“public”) chaperones such as calnexin, BiP/GRP78, protein disulphide isomerase and GRP94 [15,43]. In addition, individual GPCRs are assisted by specific (“private”) chaperones, which are required for reaching the folded state and for ER export [15,46], e.g., receptor transporting proteins/RTPs for odorant receptors [47]. This also appears to be the case for some SLC6 transporters: both, the amino acid transporters B°AT3/SLC6A18 and B°AT1/SLCA19 require collectrin or ACE2 (angiotensin-converting enzyme 2) to reach the cell surface [48–50]. In addition, the folding trajectory of GPCRs and of SLC6 transporters is also monitored on the cytosolic side. This is accomplished by a heat-shock protein (HSP) relay, which operates—at least in part—on the C-terminus (Figure 3). The evidence is as follows: when heterologously expressed the A2A-adenosine receptor accumulates in the endoplasmic reticulum [51,52]. This is not an artefact of heterologous overexpression because it can also be seen in PC12 cells, which express the A2A-receptor endogenously [53]. These receptors are stalled along their folding trajectory and have not reached their stable conformation because they accumulate in complexes with calnexin [52,54]. Mass spectrometry of tandem affinity-purified receptors shows that they are not only retrieved in complexes with ER luminal chaperones but also with abundant amounts of HSP90α and HSP70-1A [52]. In addition, the complex contains typical components of the heat-shock protein relay [52], e.g., HOP (HSC70-HSP90-organizing protein), p23 (HSP90 co-chaperone) and CHIP (C terminus of HSP70-interacting protein, an E3-ubiquitin ligase) [55]. This suggests that the stalled folding intermediates are shuttled back and forth by the heat-shock relay to allow for
refolding with two possible eventual outcomes, degradation or ER export. In fact, the flux of protein through this relay can be modified by changing the levels of individual components, e.g., depletion of HSP90 or of CHIP by siRNA-mediated downregulation results in an increase in the cell surface levels of the A2A-receptor. This can also be achieved by several inhibitors of HSP90, by kifunensine (an inhibitor of the mannosidase required for ER-associated degradation), by proteasome inhibitors [52] or by overexpressing USP4, a deubiquitinating enzyme, which interacts with the C-terminus of the A2A-receptor [51]. It can be argued that these findings are specific to the A2A-receptor: however, several crucial observations can also be recapitulated with the A1-adenosine receptor and folding-deficient mutants thereof [56]. Finally, it is worth mentioning that the receptors, which—as a consequence of these manipulations—reach the cell surface, are fully functional, i.e., they bind ligands and the enhanced expression levels translate in augmented cellular responses to agonists [51,52,56].

**Figure 3.** Extended chaperone/COPII-exchange model. Upon release from the SEC61 translocon channel (not shown), the nascent transmembrane protein (GPCR or SLC6 transporter symbolised by blue TM helices) is glycosylated and engaged by calnexin; subsequently a heat-shock protein relay is recruited to the C-terminus with sequential binding of HSP40 and HSP70, (which can be inhibited by pifithrin-μ, YM01, YM08, etc.) followed by transfer to HSP90 (which can be inhibited by DMAG = 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin = alvespimycin, radicicol and related compounds). If the client protein reaches its stable fold, the heat-shock proteins are released. This licences the C-terminus for an interaction with the cognate SEC24-isoform. The SEC23/SEC24-dimer (bow tie-shaped red and blue triangles) incorporates the protein cargo at ER exit sites (ERES) into the nascent COPII (coatomer protein complex II) coated vesicle, the curvature of which is induced by the bow tie-shape and stabilized by the outer layer COPII components SEC13/SEC31. For the sake of simplicity, the additional co-chaperones of the heat-shock protein relay (HOP, AHA1, etc.) and the additional components of the COPII machinery (the guanine nucleotide exchange factor SEC12 and the G protein SARI) are not shown. If a stable fold cannot be reached, the protein is eventually marked for ER-associated degradation (ERAD) by recruitment of an E3 ubiquitin ligase. This can be triggered by the cytosolic heat-shock protein relay (shown in the upper part) or by luminal chaperones (not shown). Initiation of ERAD is also contingent on a kifunensine-inhibited luminal mannosidase (ER degradation-enhancing alpha-mannosidase-like protein 1—EDEM1). After retrotanslocation, the protein is degraded by the proteasome, which is susceptible to inhibition by MG132, bortezomib and related compounds. Note that for the sake of clarity the series of events have been depicted in two separate schematic representations, but they occur in the same plane of the membrane.
More importantly, a very similar mechanism operates on the completely unrelated SERT (SLC6A4), although—by contrast with the A2A-receptor—SERT is assisted by HSP90β rather than HSP90α: in the endoplasmic reticulum, HSP70-1A engages the proximal segment of the C-terminus adjacent to TM12. This interaction can be visualized by FRET (fluorescence resonance energy microscopy) microscopy and is limited to nascent SERT in the ER. SERT, which resides at the cell surface, does not interact with HSP70-1A [57]. Two factors may account for this spatially restricted interaction: the binding site for HSP70-1A is no longer accessible (i) in the folded state—i.e., when the C-terminus has been correctly positioned [44]—and (ii) because the thickness of the bilayer increases progressively in the secretory pathway [58,59]; thus, the segment adjacent to TM12 is available for binding of HSP70-1A to nascent SERT in the thin bilayer of the ER but access may be sterically impeded was the lipid bilayer expands in thickness in subsequent compartments. Components of the heat-shock protein relay are retrieved in abundant amounts in complex with folding-deficient mutants of SERT. The relative abundances of HSP70-1A and of HSP90β in these complexes are inversely related and reflect the severity of the folding defect: the more severe the folding-deficient phenotype the more HSP70-1A is found in complex with the SERT mutant. Both, siRNA-induced depletion of HSP70-1A and of HSP90β and their inhibition by small molecules restore cell surface expression of functional transporters in some but not all folding-deficient mutants [57]. Finally, pharmacochaperoning of folding-deficient mutants of SERT [57] and DAT [60,61] by noribogaine results in the release of the heat-shock protein relay.

Based on these observations, it is justified to argue that equivalent principles operate in very distinct polytopic membrane proteins. Hence, it is likely that a heat-shock protein relay, which monitors the state of the C-terminus to gauge progress in the folding trajectory, is of relevance to many polytopic membrane proteins. In fact, several G protein-coupled receptors have been shown to be assisted by isoforms of HSP70/HSC70 and or HSP90, including the α2C adrenergic receptor [62], the melanocortin receptor-4 [63], the prostaglandin D2 receptor [64], the lysophosphatidic acid receptor-1 [65] and the β2-adrenergic receptor [66]. Similarly, folding of the Na+/Cl−-symporter (SLC12A3) is monitored by a cytoplasmic heat-shock protein relay [67]. The number of HSP70 (DNAK) family members is limited, i.e., there are only 11 isoforms in the human genome, which act in various cellular compartments [68]; substrate recognition is—in many instances—driven by HSP40/DNAJ family members, which are substantially more numerous, i.e., there are 41 human isoforms [68]. Currently, insights are limited, into how and which HSP40 isoforms are recruited to folding intermediates on the cytosolic side. However, there are a few examples of HSP40 isoforms that are specifically recruited to folding intermediates: ER-resident rhodopsin is recognized by HSJ1a and HSJ1b [69]; HSJ1b also targets the melanocortin receptor-4 [63]; DRIIP78 (DnaJ homolog C14) interacts with the C-terminus of the D1-receptor [70] and of the A1-adenosine receptor [10]; DNAJA1/HSP40 operates on the Na+/Cl−-symporter/SLC12A3 [67]. DNAJA1 is also retrieved in complex with SERT [71]. At the very least, these findings are consistent with a model, which posits that a cytoplasmic heat-shock protein relay operates during the folding trajectory of ER-resident polytopic membrane proteins (Figure 3). In this model [37,72], the heat-shock protein relay function as a gatekeeper: ER export can only be initiated, if the heat-shock protein is released from the C-terminus and hence the protein is licensed for ER export, because the C-terminus becomes accessible for the COPII (coatomer protein complex II)-machinery. In SLC6 transporters, the binding site for the cognate cargo receptor SEC24 isoform (SEC24C or SEC24D) resides in the C-terminus adjacent to the HSP70 binding site [73–75]. This arrangement ensures that client membrane proteins can only be exported after they have reached the fully folded state. It is worth noting, though, that steric hindrance by the heat-shock protein relay does not require the SEC24 binding site to be adjacent to the HSP70 binding site: because of the large size of the HSP90 complex and because of the annular arrangement of the transmembrane segments in polytopic membrane proteins, access of SEC24 is likely to be precluded regardless of whether the binding site is in an intracellular loop [76] or at the N-terminus [77]. We stress that this model is a simplified version, because additional chaperones [66] and gatekeepers [78,79] can monitor the folding trajectory and the assembly of oligomeric complexes prior to ER export. PRAF2 (prenylated Rab acceptor family 2) is a case in point: PRAF2 binds to the C-terminus of the GABAG-receptor-1 via an arginine-based motif (RSRR conforming to an RXR-retention motif) and
a preceding di-leucine motif; PRAF2-release is driven by the association of GABAB-receptor-1 with the GABAB-receptor-2 [78,79]. Thus, assembly of the heterodimer and its subsequent ER export is under the control of PRAF2. This arrangement presumably allows for monitoring of the folding trajectory of the GABAB-receptor-2, because the heterodimer is only likely to form after the GABAB-receptor-2 has reached its stable fold. Finally, the SEC24 binding site can also be supplied in trans by an associated escort protein [80], which is likely to be recruited after completion of folding.

3. Remedying Folding Deficiency: Scaffolding vs. Relaxing Quality Control

The energy landscape of protein folding is rugged [55]: packing individual helices results in a drop in energy and thus produces local minima in the energy landscape, but rearranging these helices may destabilize interactions, which have already been formed. Thermal motion aggravates the problem. Unsurprisingly, in many instances, lowering the temperature increases the probability of productive folding and rescues folding-deficient variants. This has also been documented for GPCRs [81,82]. In practice, this approach cannot be pursued to remedy a folding disease unless the misfolded protein is expressed in testis [83]. Specific ligands are thought to act as scaffolds; by binding to folding intermediates, they allow the folding trajectory to move forward. G protein-coupled receptors have an othosteric binding site, where the cognate (endogenous) agonist(s) and antagonists bind. In addition, G protein-coupled receptors have several binding sites for allosteric activators or inhibitors [84]. Pharmacochaperoning by allosteric ligands has not yet been explored to the same extent as that of orthosteric ligands: it worth noting that allosteric ligands capable of rescuing misfolded GPCRs have been discovered for the calcium sensing receptor [85], the receptors for FSH/follicle stimulating hormone [86] and LH/luteinizing hormone [87] and the wnt-receptor frizzled-4 [88]. In all these instances, the cognate ligand is known to bind to an N-terminal domain rather than within the hydrophobic core. Thus, it is conceivable that these allosteric pharmacochaperones bind to the hydrophobic core within the region, where the orthosteric binding site lies in rhodopsin-like GPCRs. In fact, many folding-deficient G protein-coupled receptor mutants can be rescued by treating the cells with orthosteric antagonists [15]. Cell-permeable agonists also work [10]. However, their therapeutic potential is limited, because in vivo their efficacy as pharmacochaperones is compounded by agonist-induced desensitization of the receptor. The pharmacochaperoning action of orthosteric ligands relies—at least in part—on the presence of proteinaceous chaperones heat-shock proteins. This conclusion is based on the following observations: fully functional (i.e., ligand- and G protein-binding competent) GPCRs can be expressed in E. coli [89,90] including the A1-adenosine receptor [91]. However, antagonists fail to rescue folding-deficient mutants of the A1-receptor, if these are expressed in E. coli, although in mammalian cells these antagonists effectively pharmacochaperone the very same receptors [10].

Pharmacochaperoning folding-deficient SLC6 transporter mutants is less straightforward: typical inhibitors and substrates fail to restore their export from the ER and their cell surface localization [43,92]. The failure of inhibitors can be rationalized by taking into account that inhibitors bind to the outward facing conformation, which requires the presence of Na+ ions. However, there are not appreciable levels of Na+ in the ER lumen [37], the topological equivalent to the extracellular face of the plasma membrane. Hence, inhibitors cannot bind to ER-resident SLC6 transporters. It is also not surprising that (membrane-permeable) substrates are ineffective: substrates drive conformational transitions and are thus unlikely to stabilize a folding intermediate. The ionic composition of the ER and the resulting transmembrane gradient predicts that the folding trajectory of SLC6 transporters ought to passes through the inward-facing conformation. In fact, ibogaine and its demethylated metabolite noribogaine, which bind to the inward-facing conformation of SERT and DAT [93,94], were the first effective pharmacochaperones to be identified [43,57,60]. Similarly, mutations, which trap SERT in the inward-facing state [95], act as second site suppressors and restore ER-export of folding-deficient SERT mutants [57]. Subsequently, additional compounds were identified, which pharmacochaperone folding-deficient DAT [92] and SERT mutants [96]. These compounds act as atypical inhibitors of the
transporter, e.g., bupropion in DAT [92], or as atypical substrates, presumably because they also have a high affinity for the inward-facing state of SERT [96].

The heat-shock protein relay, which operates on the cytosolic side, is an obvious target: inhibitors of both HSP70 [97] and HSP90 [98] are being developed for the treatment of various cancers. It has long been known that relaxing the quality control in the ER can rescue folding-deficient membrane proteins: inhibition of SERCA (the sarcoplasmic-endoreticular Ca$^{2+}$-ATPase) by thapsigargin depletes the ER of calcium and thus abrogates the activity of calnexin. This allows folding-deficient CFTR-ΔF508 to reach the cell surface [99], albeit not in quantities sufficient to be clinically relevant [100]. Similarly, inhibition of the proteasome-dependent ER-associated degradation also allows CFTR-ΔF508 to escape to the cell surface [101]. The effect of proteasomal inhibition is not restricted to CFTR-ΔF508: an increase in ER export and surface expression of functional receptors can also be seen with GPCRs [51,52,102]. Based on these observations, it appears that ER quality control is stringent and overprotective: ER quality control is programmed to err on the safe side, which leads to the elimination of functional protein molecules. Thus, relaxing ER quality control may allow for increased ER export of mutant membrane proteins without jeopardizing cellular viability. The chaperone-COPII exchange model (Figure 3) posits that a heat-shock protein relay monitors progression of SLC6 transporters through their folding trajectory. This model also predicts that inhibition of the heat-shock protein relay relaxes ER quality control. This prediction has been verified in several instances: (i) as mentioned above inhibitors of HSP90 enhance surface expression of the $\alpha_2\Delta$-receptor [52] and of the $\nu_2$-vasopressin receptor [103]. Similarly, ER export and cell surface expression of some folding-deficient SERT mutants [57] and disease-associated DAT mutants [61] can be restored by inhibitors of HSP90; (ii) The HSP70 inhibitor pifithrin-µ (2-phenylethynesulfonamide) is also effective at restoring the surface expression of several folding-deficient SERT [57] and DAT mutants [60,61]. Importantly, pifithrin-µ also rescues folding-defective DAT mutants in vivo: Drosophila melanogaster, which lack a functional DAT, are sleepless [104]. Reduced sleep length is also seen true for flies harbouring folding-deficient DAT mutants [60,61,105]. Pifithrin-µ is as effective as the pharmacochaperone noribogaine in restoring sleep, if these flies are administered the drugs via their food [60,61]. Similarly, the increase in $\nu_2$-receptor expression, which is induced by HSP90 inhibitors, is also seen in people: hyponatraemia is a side effect that was frequently observed in cancer patients undergoing clinical trials with various HSP90 inhibitors [103].

Neither inhibitors of HSP90 nor HSP70 are universally effective in rescuing folding deficient mutants. This can be rationalized by taking into account the fact that their action depends on the point, at which the folding intermediates are stalled in the folding trajectory. Accordingly, when combined with the pharmacochaperone noribogaine, all possible types of interactions were observed: depending on the nature of the mutation in SERT, HSP inhibitors (i) potentiated the action of noribogaine by shifting the concentration of noribogaine to the left; (ii) they were additive by increasing the maximum effect on cell surface expression without any appreciable change in EC$_{50}$ of noribogaine or (iii) they shifted the concentration-response curve to the right [57]. It is also worth noting that HSP70 inhibitors are not equivalent, because they target different domains in the protein [106]. Pifithrin-µ binds to the C-terminal substrate/peptide-binding domain and suppresses the association between HSP70 and some of its co-factors/co-chaperones (e.g., HSP40) [107]. In contrast, VER155008, for instance, is an adenosine derivative that mimics the action of ADP in the HSP70 cycle and thus traps the substrate–HSP70 complex [108]. Contrary to pifithrin-µ, VER155008 does not rescue folding-deficient SERT mutants but increases their accumulation in the ER [57].

Based on these observations, it is safe to conclude that that inhibition of HSPs is a viable option to rescue folding-deficient polytopic membrane proteins, but that many different compounds will be needed to achieve relaxation of ER quality control at the stage, where a given mutant is stalled. In vivo, orthosteric ligands, which occupy the substrate binding site in a transporter or the agonist binding site, have a major limitation: while they rescue their target, they also block it. Accordingly, they must be given in a pulsatile manner: the folding defect of a GnRH-receptor can be corrected in
mice by administration of a GnRH-receptor antagonist every three days [109]. Similarly, migalastat is administered to patients every other day to restore the function of lysosomal α-galactosidase in Fabry’s disease [3]. When combined with the appropriate HSP-inhibitor, the pharmacochaperoning action of the orthosteric ligand may be selectively potentiated, because the compounds act synergistically on the folding intermediates in the ER. There is at least one proof-of-concept experiment that supports this assumption: addition of pifithrin-μ substantially enhanced the ability of low doses of noribogaine to restore sleep in flies harbouring a folding-deficient DAT mutant [60].

Acknowledgments: H.M. Mazhar Asjad is a recipient of a fellowship from the Higher Education Commission of Pakistan; Shahrooz Nasrollahi-Shirazi is supported by the doctoral programme CCHD (Cell Communication in Health and Disease), which is jointly funded by the Austrian Science Fund (W1205) and the Medical University of Vienna. Work from the authors’ laboratory is funded by grants of the Austrian Science Fund (P27518-B27 and SFB35-10 to Sonja Sucic and Michael Freissmuth, respectively).

Author Contributions: All authors contributed to writing the text and approved the final version.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Morello, J.P.; Petäjä-Repo, U.E.; Bichet, D.G.; Bouvier, M. Pharmacological chaperones: A new twist on receptor folding. *Trends Pharmacol. Sci.* 2000, 21, 466–469. [CrossRef]
2. Leidenheimer, N.J.; Ryder, K.G. Pharmacological chaperoning: A primer on mechanism and pharmacology. *Pharmacol. Res.* 2014, 83, 10–19. [CrossRef] [PubMed]
3. Germain, D.P.; Hughes, D.A.; Nicholls, K.; Bichet, D.G.; Giugliani, R.; Wilcox, W.R.; Feliciani, C.; Shankar, S.P.; Ezgu, F.; Amartino, H.; et al. Treatment of Fabry’s disease with the pharmacologic chaperone migalastat. *N. Engl. J. Med.* 2016, 375, 545–555. [CrossRef] [PubMed]
4. Van Goor, F.; Hadida, S.; Grootenhuis, P.D.; Burton, B.; Stack, J.H.; Straley, K.S.; Decker, C.J.; Miller, M.; McCartney, J.; Olson, E.R.; et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. *Proc. Natl. Acad. Sci. USA* 2011, 108, 18843–18848. [CrossRef] [PubMed]
5. Alderman, E.L.; Coltart, D.J.; Wettach, G.E.; Harrison, D.C. Coronary artery syndromes after sudden propranolol withdrawal. *Ann. Intern. Med.* 1974, 81, 625–627. [CrossRef] [PubMed]
6. Miller, R.R.; Olson, H.G.; Amsterdam, E.A.; Mason, D.T. Propranolol-withdrawal rebound phenomenon. Exacerbation of coronary events after abrupt cessation of antianginal therapy. *N. Engl. J. Med.* 1975, 293, 416–418. [CrossRef] [PubMed]
7. Aarons, R.D.; Nies, A.S.; Gal, J.; Hegstrand, L.R.; Molinoff, P.B. Elevation of β-adrenergic receptor density in human lymphocytes after propranolol administration. *J. Clin. Invest.* 1980, 65, 949–957. [CrossRef] [PubMed]
8. Nanoff, C.; Schütz, W. Characterization of the β-adrenoceptor blocking property of diprafenone in rats: Stereoselective interaction, subtype specificity, and sensitization. *J. Cardiovasc. Pharmacol.* 1991, 18, 837–842. [CrossRef] [PubMed]
9. Nasrollahi-Shirazi, S.; Sucic, S.; Yang, Q.; Freissmuth, M.; Nanoff, C. Comparison of the β-adrenergic receptor antagonists landiolol and esmolol: Receptor selectivity, partial agonism, and pharmacochaperoning actions. *J. Pharmacol. Exp. Ther.* 2016, 359, 73–81. [CrossRef] [PubMed]
10. Málaga-Díéguez, L.; Yang, Q.; Bauer, J.; Pankevych, H.; Freissmuth, M.; Nanoff, C. Pharmacochaperoning of the A1 adenosine receptor is contingent on the endoplasmic reticulum. *Mol. Pharmacol.* 2010, 77, 940–952. [CrossRef] [PubMed]
11. Lister, H.A.; Miwa, J.M.; Srinivasa, R. Psychiatric drugs bind to classical targets within early exocytotic pathways: Therapeutic effects. *Biol. Psychiatry* 2012, 72, 907–915. [CrossRef] [PubMed]
12. Pauling, L.; Itano, H.A.; Singer, S.J.; Wells, I.C. Sickle cell anemia a molecular disease. *Science* 1949, 110, 543–548. [CrossRef] [PubMed]
13. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: A systematic analysis for the Global Burden of Disease Study 2015. *Lancet* 2016, 388, 1545–1602.
Morello, J.P.; Salahpour, A.; Laperrière, A.; Bernier, V.; Arthus, M.F.; Lonergan, M.; Petijä-Repo, U.; Angers, S.; Morin, D.; Bichet, D.G.; et al. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J. Clin. Investig. 2000, 105, 887–895. [CrossRef] [PubMed]

15. Tao, Y.X.; Conn, P.M. Chaperoning G protein-coupled receptors: From cell biology to therapeutics. Endocr. Rev. 2014, 35, 602–647. [CrossRef] [PubMed]

16. Sahni, N.; Yi, S.; Taipale, M.; Bass, J.I.; Coulombe-Huntington, J.; Yang, F.; Peng, J.; Weile, J.; Karras, G.I.; Wang, Y.; et al. Widespread macromolecular interaction perturbations in human genetic disorders. Cell 2015, 161, 647–660. [CrossRef] [PubMed]

17. Hahn, M.K.; Robertson, D.; Blakely, R.D. A mutation in the human norepinephrine transporter gene (SLC6A2) associated with orthostatic intolerance disrupts surface expression of mutant and wild-type transporters. J. Neurosci. 2003, 23, 4470–4478. [PubMed]

18. Rosenberg, E.H.; Almeida, L.S.; Kleefstra, T.; de Grauw, R.S.; Yntema, H.G.; Bahi, N.; Moraine, C.; Ropers, H.H.; Fryns, J.P.; de Grauw, T.J.; et al. High prevalence of SLC6A8 deficiency in X-linked mental retardation. Am. J. Hum. Genet. 2004, 75, 97–105. [CrossRef] [PubMed]

19. Mancini, G.M.; Catsman-Berrevoets, C.E.; de Coo, I.F.; Aarsen, F.K.; Kamphoven, J.H.; Huijmans, J.G.; Duran, M.; van der Knaap, M.S.; Jakobs, C.; Salomons, G.S. Two novel mutations in SLC6A8 cause creatine transporter defect and distinctive X-linked mental retardation in two unrelated Dutch families. Am. J. Med. Genet. A 2005, 132, 288–295. [CrossRef] [PubMed]

20. Clark, A.J.; Rosenberg, E.H.; Almeida, L.S.; Wood, T.C.; Jakobs, C.; Stevenson, R.E.; Schwartz, C.E.; Salomons, G.S. X-linked creatine transporter (SLC6A8) mutations in about 1% of males with mental retardation of unknown etiology. Hum. Genet. 2006, 119, 604–610. [CrossRef] [PubMed]

21. Lion-François, L.; Cheillan, D.; Pitelet, G.; Acquaviva-Bourdain, C.; Bussy, G.; Cotton, F.; Guibaud, L.; Gérard, D.; Rivier, C.; Vianey-Saban, C.; et al. High frequency of creatine deficiency syndromes in patients with unexplained mental retardation. Neurology 2006, 67, 1713–1714. [CrossRef] [PubMed]

22. Rosenberg, E.H.; Martínez Muñoz, C.; Betsalel, O.T.; van Dooren, S.J.; Fernandez, M.; Jakobs, C.; de Grauw, T.J.; Kleefstra, T.; Schwartz, C.E.; Salomons, G.S. Functional characterization of missense variants in the creatine transporter gene (SLC6A8): Improved diagnostic application. Hum. Mutat. 2007, 28, 890–896. [CrossRef] [PubMed]

23. Alcaide, P.; Rodriguez-Pombo, P.; Ruiz-Sala, P.; Ferrer, I.; Castro, P.; Ruiz Martin, Y.; Merinero, B.; Ugarte, M. A new case of creatine transporter deficiency associated with mild clinical phenotype and a novel mutation in the SLC6A8 gene. Dev. Med. Child Neurol. 2010, 52, 215–217. [CrossRef] [PubMed]

24. DesRoches, C.L.; Patel, J.; Wang, P.; Minassian, B.; Salomons, G.S.; Marshall, C.R.; Mercimek-Mahmutoglu, S. Estimated carrier frequency of creatine transporter deficiency in females in the general population using functional characterization of novel missense variants in the SLC6A8 gene. Mol. Genet. Metab. Rep. 2016, 8, 20–23. [CrossRef] [PubMed]

25. Comeaux, M.S.; Wang, J.; Wang, G.; Kleppe, S.; Zhang, V.W.; Schmitt, E.S.; Craigen, W.J.; Renaud, D.; Sun, Q.; Wong, L.J. Biochemical, molecular, and clinical diagnoses of patients with cerebral creatine deficiency syndromes. Mol. Genet. Metab. 2013, 109, 260–268. [CrossRef] [PubMed]

26. Ardon, O.; Procter, M.; Mao, R.; Longo, N.; Landau, Y.E.; Shilon-Hadass, A.; Gabis, L.V.; Hoffmann, C.; Tzadok, M.; Heimer, G.; et al. Creatine transporter deficiency: Novel mutations and functional studies. Mol. Genet. Metab. Rep. 2016, 10, 59–64. [CrossRef] [PubMed]

27. Betsalel, O.T.; Pop, A.; Rosenberg, E.H.; Fernandez-Ojeda, M.; Creatine Transporter Research Group; Jakobs, C.; Salomons, G.S. Detection of variants in SLC6A8 and functional analysis of unclassified missense variants. Mol. Genet. Metab. 2012, 105, 596–601. [CrossRef] [PubMed]

28. Uemura, T.; Ito, S.; Ohta, Y.; Tachikawa, M.; Wada, T.; Terasaki, T.; Ohtsuki, S. Abnormal N-glycosylation of a novel missense creatine transporter mutant, G561R, associated with cerebral creatine deficiency syndromes alters transporter activity and localization. Biol. Pharm. Bull. 2017, 40, 49–55. [CrossRef] [PubMed]

29. Reeves, M.I.; Harvey, K.; Pearce, B.R.; Chung, S.K.; Duguid, I.C.; Thomas, P.; Beatty, S.; Graham, G.E.; Armstrong, I.; Shiang, R.; et al. Mutations in the gene encoding GlyT2 (SLC6A5) define a presynaptic component of human startle disease. Nat. Genet. 2006, 38, 801–806. [CrossRef] [PubMed]
30. Giménez, C.; Pérez-Siles, G.; Martínez-Villarreal, J.; Arribas-Gonzalez, E.; Jiménez, E.; Núñez, E.; de Juan-Sanz, J.; Fernández-Sánchez, E.; García-Tardón, N.; Ibáñez, I.; et al. A novel dominant hyperekplexia mutation Y705C alters trafficking and biochemical properties of the presynaptic glycine transporter GlyT2. *J. Biol. Chem.* 2012, 287, 28986–29002. [CrossRef] [PubMed]

31. Kurian, M.A.; Zhen, J.; Cheng, S.Y.; Li, Y.; Mordekar, S.R.; Jardine, P.; Morgan, N.V.; Meyer, E.; Tee, L.; Pasha, S.; et al. Homozygous loss-of-function mutations in the gene encoding the dopamine transporter are associated with infantile parkinsonism-dystonia. *J. Clin. Investig.* 2009, 11, 1595–1603. [CrossRef] [PubMed]

32. Kurian, M.A.; Li, Y.; Zhen, J.; Meyer, E.; Hai, N.; Christen, H.J.; Hoffmann, G.F.; Jardine, P.; von Moers, A.; Mordekar, S.R.; et al. Clinical and molecular characterisation of hereditary dopamine transporter deficiency syndrome: An observational cohort and experimental study. *Lancet Neurol.* 2011, 10, 54–62. [CrossRef]

33. Ng, J.; Zhen, J.; Meyer, E.; Erreger, K.; Li, Y.; Kakar, N.; Ahmad, J.; Thiele, H.; Kubisch, C.; Rider, N.L.; et al. Dopamine transporter deficiency syndrome: Phenotypic spectrum from infancy to adulthood. *Brain* 2014, 137, 1107–1119. [CrossRef] [PubMed]

34. Palmer, S.; Towne, M.C.; Pearl, P.L.; Pelletier, R.C.; Genetti, C.A.; Shi, J.; Beggs, A.H.; Agrawal, P.B.; Brownstein, C.A. SLC6A1 mutation and ketogenic diet in epilepsy with myoclonic-atonic seizures. *Pediatr. Neurol.* 2016, 64, 77–79. [CrossRef] [PubMed]

35. Cymer, F.; von Heijne, G.; White, S.H. Mechanisms of integral membrane protein insertion and folding. *J. Mol. Biol.* 2015, 427, 999–1022. [CrossRef] [PubMed]

36. De Marothy, M.T.; Elofsson, A. Marginally hydrophobic transmembrane α-helices shaping membrane protein folding. *Protein Sci.* 2015, 24, 1057–1074. [CrossRef] [PubMed]

37. Chiba, P.; Freissmuth, M.; Stockner, T. Defining the blanks—Pharmacochaperoning of SLC6 transporters and ABC transporters. *Pharmacol. Res.* 2014, 83, 63–73. [CrossRef] [PubMed]

38. Shim, J.Y. Transmembrane helical domain of the cannabinoid CB1 receptor. *Biophys. J.* 2009, 96, 3251–3262. [CrossRef] [PubMed]

39. Nanoff, C.; Freissmuth, M. ER-bound steps in the biosynthesis of G protein-coupled receptors. *Subcell. Biochem.* 2012, 63, 1–21. [PubMed]

40. Pankevych, H.; Korkhov, V.; Freissmuth, M.; Nanoff, C. Truncation of the A1 adenosine receptor reveals distinct roles of the membrane-proximal carboxyl terminus in receptor folding and G protein coupling. *J. Biol. Chem.* 2003, 278, 30283–30293. [CrossRef] [PubMed]

41. Farhan, H.; Korkhov, V.M.; Paulitschke, V.; Dorostkar, M.M.; Scholze, P.; Kudlacek, O.; Freissmuth, M.; Sitte, H.H. Two discontinuous segments in the carboxyl terminus are required for membrane targeting of the rat gamma-aminobutyric acid transporter-1 (GAT1). *J. Biol. Chem.* 2004, 279, 28553–28563. [CrossRef] [PubMed]

42. Larsen, M.B.; Fjorback, A.W.; Wilborg, O. The C-terminus is critical for the functional expression of the human serotonin transporter *Biochemistry* 2006, 45, 1331–1337. [CrossRef] [PubMed]

43. El-Kasaby, A.; Just, H.; Malle, E.; Stolt-Bergner, P.C.; Sitte, H.H.; Freissmuth, M.; Kudlacek, O. Mutations in the carboxyl-terminal SEC24 binding motif of the serotonin transporter impair folding of the transporter. *J. Biol. Chem.* 2010, 285, 39201–39210. [CrossRef] [PubMed]

44. Koban, F.; El-Kasaby, A.; Häusler, C.; Stockner, T.; Simbrunner, B.M.; Sitte, H.H.; Freissmuth, M.; Sucic, S. A salt bridge linking the first intracellular loop with the C terminus facilitates the folding of the serotonin transporter. *J. Biol. Chem.* 2015, 290, 13263–13278. [CrossRef] [PubMed]

45. Shim, J.Y. Transmembrane helical domain of the cannabinoid CB1 receptor. *Biophys. J.* 2009, 96, 3251–3262. [CrossRef] [PubMed]

46. Saito, H.; Kubota, M.; Roberts, R.W.; Chi, Q.; Matsumani, H. RTP family members induce functional expression of mammalian odorant receptors. *Cell* 2004, 119, 679–691. [CrossRef] [PubMed]

47. Singer, D.; Camargo, S.M.; Huggel, K.; Romeo, E.; Danilczyk, U.; Kuba, K.; Chesnov, S.; Caron, M.G.; Penninger, J.M.; Verney, F. Orphan transporter SLC6A18 is renal neutral amino acid transporter B0AT3. *J. Biol. Chem.* 2009, 284, 19953–19960. [CrossRef] [PubMed]
49. Camargo, S.M.; Singer, D.; Makrides, V.; Huggel, K.; Pos, K.M.; Wagner, C.A.; Kuba, K.; Danilczyk, U.; Skovby, F.; Kleta, R.; et al. Tissue-specific amino acid transporter partners ACE2 and collectrin differentially interact with hartnup mutations. *Gastroenterology* 2009, 136, 872–882. [CrossRef] [PubMed]

50. Kowalczuk, S.; Bröer, A.; Tietze, N.; Vanslambrouck, J.M.; Rasko, J.E.; Bröer, S. A protein complex in the brush-border membrane explains a Hartnup disorder allele. *FASEB J.* 2008, 22, 2880–2887. [CrossRef] [PubMed]

51. Milojevic, T.; Reiterer, V.; Stefan, E.; Korkhov, V.M.; Dorostkar, M.M.; Duzea, E.; Ogris, E.; Boehm, S.; Freissmuth, M.; Nanoff, C. The ubiquitin-specific protease Usp4 regulates the cell surface level of the A2A receptor. *Mol. Pharmacol.* 2016, 90, 1083–1094.

52. Bergmayr, C.; Thurmer, P.; Keuerleber, S.; Kudlacek, O.; Nanoff, C.; Freissmuth, M.; Gruber, C.W. Recruitment of a cytoplasmic chaperone relay by the A2A adenosine receptor. *J. Biol. Chem.* 2013, 288, 28831–28844. [CrossRef] [PubMed]

53. Arslan, G.; Kull, B.; Fredholm, B.B. Anoxia redistributes adenosine A2A receptors in PC12 cells and increases receptor-mediated formation of cAMP. *Naunyn-Schmiedeberg’s Arch. Pharmacol.* 2002, 365, 150–157. [CrossRef] [PubMed]

54. Korkhov, V.M.; Milan-Lobo, L.; Zuber, B.; Farhan, J.A.; Freissmuth, M.; Sitte, H.H. Peptide-based interactions with calnexin target misassembled membrane proteins into endoplasmic reticulum-derived multilamellar bodies. *J. Mol. Biol.* 2008, 378, 337–352. [CrossRef] [PubMed]

55. Hartl, F.U.; Bracher, A.; Hayer-Hartl, M. Molecular chaperones in protein folding and proteostasis. *Nature* 2011, 475, 324–332. [CrossRef] [PubMed]

56. Kusek, J.; Yang, Q.; Witek, M.; Gruber, C.W.; Nanoff, C.; Freissmuth, M. Chaperoning of the A1 adenosine receptor by endogenous adenosine—An extension of the retaliatory metabolite concept. *Mol. Pharmacol.* 2015, 87, 39–51. [CrossRef] [PubMed]

57. El-Kasaby, A.; Koban, F.; Sitte, H.H.; Freissmuth, M.; Sucic, S. A cytosolic relay of heat shock proteins HSP70-1A and HSP90β monitors the folding trajectory of the serotonin transporter. *J. Biol. Chem.* 2014, 289, 28897–29000. [CrossRef] [PubMed]

58. Sharpe, H.J.; Stevens, T.J.; Munro, S. A comprehensive comparison of transmembrane domains reveals organelle-specific properties. *Cell* 2010, 142, 158–169. [CrossRef] [PubMed]

59. Holthuis, J.C.; Menon, A.K. Lipid landscapes and pipelines in membrane homeostasis. *Nature* 2014, 510, 48–57. [CrossRef] [PubMed]

60. Kasture, A.; El-Kasaby, A.; Szöllösi, D.; Asjad, H.M.M.; Grimm, A.; Stockner, T.; Hummel, T.; Freissmuth, M.; Sucic, S. Functional rescue of a misfolded Drosophila melanogaster dopamine transporter mutant associated with a sleepless phenotype by pharmacological chaperones. *J. Biol. Chem.* 2016, 291, 20876–20890. [CrossRef] [PubMed]

61. Asjad, H.M.M.; Kasture, A.; El-Kasaby, A.; Sackel, M.; Hummel, T.; Freissmuth, M.; Sucic, S. Pharmacochaperoning in a Drosophila model system rescues human dopamine transporter variants associated with infantile/juvenile parkinsonism. *J. Biol. Chem.* 2017, in press. [CrossRef] [PubMed]

62. Filipkeun, C.M.; de Vries, R.; Danser, A.H.J.; Kapusta, D.R. Modulation of α2C adrenergic receptor temperature-sensitive trafficking by HSP90. *Biochim. Biophys. Acta Mol. Cell Res.* 2011, 1813, 346–357. [CrossRef] [PubMed]

63. Meimardou, E.; Gooljar, S.B.; Ramnarace, N.; Anthonypillai, L.; Clark, A.J.L.; Chapple, J.P. The cytosolic chaperone Hsc70 promotes traffic to the cell surface of intracellular retained melanocortin-4 receptor mutants. *Mol. Endocrinol.* 2011, 25, 1650–1660. [CrossRef] [PubMed]

64. Binda, C.; Génier, S.; Cartier, A.; Larrivée, J.F.; Stankova, J.; Young, J.C.; Parent, J.L. AG protein-coupled receptor and the intracellular synthase of its agonist functionally cooperate. *J. Cell Biol.* 2014, 204, 377–393. [CrossRef] [PubMed]

65. Génier, S.; DeGrandmaison, J.; Moreau, P.; Labrecque, P.; Hebert, T.E.; Parent, J.L. Regulation of GPCR expression through an interaction with CCT7, a subunit of the CCT/TRiC complex. *Mol. Biol. Cell* 2016, 27, 3800–3812. [CrossRef] [PubMed]

66. Zhao, J.; Wei, J.; Bowser, R.K.; Dong, S.; Xiao, S.; Zhao, Y. Molecular regulation of lysophosphatidic acid receptor 1 trafficking to the cell surface. *Cell. Signal.* 2014, 26, 2406–2411. [CrossRef] [PubMed]

67. Donnelly, B.F.; Needham, P.G.; Snyder, A.C.; Roy, A.; Khadem, S.; Brodsky, J.L.; Subramanya, A.R. Hsp70 and Hsp90 multichaperone complexes sequentially regulate thiazide-sensitive cotransporter endoplasmic reticulum-associated degradation and biogenesis. *J. Biol. Chem.* 2013, 288, 13124–13135. [CrossRef] [PubMed]
87. Newton, C.L.; Whay, A.M.; McArdle, C.A.; Zhang, M.; van Koppen, C.J.; van de Lagemaat, R.; Segaloff, D.L.; Janovick, J.A.; Maya-N
88. Jeyaraj, S.C.; Chotani, M.A.; Mitra, S.; Gregg, H.E.; Flavahan, N.A.; Morrison, K.J. Cooling evokes redistribution of the A2A-adenosine receptor. Biochim. Biophys. Acta 2011, 1808, 1350–1357. [CrossRef] [PubMed]
89. Doly, S.; Shirvani, H.; Gata, G.; Meye, F.J.; Emerit, M.B.; Enslen, H.; Achour, L.; Pardo-Lopez, L.; Yang, S.K.; Armand, V.; et al. GABA_A receptor cell-surface export is controlled by an endoplasmic reticulum gatekeeper. Mol. Psychiatry 2016, 21, 480–490. [CrossRef] [PubMed]
90. Sauvageau, E.; Rochdi, M.D.; Oueslati, M.; Hamdan, F.F.; Percherancier, Y.; Simpson, J.C.; Pepperkok, R.; Bouvier, M. CNIII interacts with newly synthesized GPCR and controls their export from the endoplasmic reticulum. Traffic 2014, 15, 383–400. [CrossRef] [PubMed]
91. Jaquette, J.; Segaloff, D.L. Temperature sensitivity of some mutants of the lutropin/choriogonadotropin receptor. Endocrinology 1997, 138, 85–91. [CrossRef] [PubMed]
92. Jeyaraj, S.C.; Chatani, M.A.; Mitra, S.; Gregg, H.E.; Flavahan, N.A.; Morrison, K.J. Cooling evokes redistribution of α2C-adrenoceptors from Golgi to plasma membrane in transfected human embryonic kidney 293 cells. Mol. Pharmacol. 2001, 60, 1195–1200. [PubMed]
93. Iiri, T.; Herzmark, P.; Nakamoto, J.M.; van Dop, C.; Bourne, H.R. Rapid GDP release from Gαs in patients with gain and loss of endocrine function. Nature 1994, 371, 164–168. [CrossRef] [PubMed]
94. Gentry, P.R.; Sexton, P.M.; Christopoulos, A. Novel Allosteric Modulators of G Protein-coupled Receptors. J. Biol. Chem. 2015, 290, 19478–19488. [CrossRef] [PubMed]
95. White, E.; McKenna, J.; Cavanaugh, A.; Breitwieser, G.E. Pharmacochaperone-mediated rescue of calcium-sensing receptor loss-of-function mutants. Mol. Endocrinol. 2009, 23, 1115–1123. [CrossRef] [PubMed]
96. Janovick, J.A.; Maya-Nuñez, G.; Uloa-Aguirre, A.; Huhtaniemi, I.T.; Dias, J.A.; Verborst, P.; Connn, P.M. Increased plasma membrane expression of human follicle-stimulating hormone receptor by a small molecule thienopyridimidine. Mol. Cells. Endocrinol. 2009, 298, 28–48. [CrossRef] [PubMed]
97. Newton, C.L.; Whay, A.M.; McArdle, C.A.; Zhang, M.; van Koppen, C.J.; van de Lagemaat, R.; Segaloff, D.L.; Millar, R.P. Rescue of expression and signaling of human luteinizing hormone G protein-coupled receptor mutants with an allosterically binding small-molecule agonist. Proc. Natl. Acad. Sci. USA 2011, 108, 7172–7176. [CrossRef] [PubMed]
106. Assimon, V.A.; Gillies, A.T.; Rauch, J.N.; Gestwicki, J.E. Hsp70 protein complexes as drug targets. *Nat. Chem. Biol.* 2015, 11, 280–286. [CrossRef] [PubMed]

104. Kume, K.; Kume, S.; Park, S.K.; Hirsh, J.; Jackson, F.R. Dopamine is a regulator of arousal in the fruit fly. *Proc. Natl. Acad. Sci. USA* 1991, 88, 8548–8552. [CrossRef] [PubMed]

103. Yang, Q.; Puhm, F.; Freissmuth, M.; Nanoff, C. Hyponatremia and V2 vasopressin receptor upregulation: A result of HSP90 inhibition. *J. Biol. Chem.* 2007, 282, 29441–29447. [CrossRef] [PubMed]

102. Petäjä-Repo, U.E.; Hogue, M.; Laperriere, A.; Bhalla, S.; Walker, P.; Bouvier, M. Newly synthesized human serotonin 5-HT1A receptor in *Escherichia coli*. Ligand binding properties and interaction with recombinant G protein α-subunits. *J. Biol. Chem.* 1992, 267, 8200–8282. [PubMed]

101. Vij, N.; Fang, S.; Zeitlin, P.L. Selective inhibition of endoplasmic reticulum-associated degradation rescues ΔF508-CFTR protein in cystic fibrosis epithelial cells. *Nat. Med.* 2002, 8, 485–492. [CrossRef] [PubMed]

100. Grubb, B.R.; Gabriel, S.E.; Mengos, A.; Gentzsch, M.; Randell, S.H.; Van Heeckeren, A.M.; Knowles, M.R.; Drumm, M.L.; Riordan, J.R.; Boucher, R.C. SERCA pump inhibitors do not correct biosynthetic arrest of ΔF508-CFTR in cystic fibrosis. *Am. J. Respir. Cell Mol. Biol.* 2006, 34, 355–363. [CrossRef] [PubMed]

99. Egan, M.E.; Glöckner-Pagel, J.; Ambrose, C.; Cahill, P.A.; Pappoe, L.; Balamuth, N.; Cho, E.; Canny, S.; Sandtner, W.; Freissmuth, M. Conformational state interactions provide clues to the pharmacochaperone potential of serotonin transporter partial substrates. *J. Biol. Chem.* 2012, 287, 18524–18534. [CrossRef] [PubMed]

98. Neckers, L.; Workman, P. Hsp90 molecular chaperone inhibitors: Are we there yet? *Cancer Lett.* 2012, 325, 117–124. [CrossRef] [PubMed]

97. Goloudina, A.R.; Demidov, O.N.; Garrido, C. Inhibition of HSP70: A challenging anti-cancer strategy. *Curr. Pharm. Des.* 2009, 15, 17369–17378. [CrossRef] [PubMed]

96. Bhat, S.; Hasenhuetl, P.S.; Kasture, A.; El-Kasaby, A.; Baumann, M.H.; Blough, B.E.; Sucic, S.; Sandtner, W.; Freissmuth, M. Species difference in the G protein selectivity of the human and bovine A1-adenosinereceptor. *J. Biol. Chem.* 2005, 280, 17369–17384. [CrossRef] [PubMed]

95. Korkhov, V.M.; Holy, M.; Freissmuth, M.; Sitte, H.H. The conserved glutamate (Glu136) in transmembrane domain 2 of the serotonin transporter is required for the conformational switch in the transport cycle. *J. Biol. Chem.* 2016, 281, 13439–13448. [CrossRef] [PubMed]

94. Bulling, S.; Schicker, K.; Zhang, Y.W.; Steinkellner, T.; Stockner, T.; Gruber, C.W.; Boehm, S.; Freissmuth, M.; Rudnick, G.; Sitte, H.H.; et al. The mechanistic basis for noncompetitive ibogaine inhibition of serotonin and dopamine transporters. *J. Biol. Chem.* 2012, 287, 18524–18534. [CrossRef] [PubMed]

93. Jacobs, M.T.; Zhang, Y.W.; Campbell, S.D.; Rudnick, G. Ibogaine, a noncompetitive inhibitor of serotonin transport, acts by stabilizing the cytoplasm-facing state of the transporter. *J. Biol. Chem.* 2007, 282, 29441–29447. [CrossRef] [PubMed]

92. Beerepoot, P.; Lam, V.M.; Salahpour, A. Pharmacological chaperones of the dopamine trans-porter rescue dopamine transporter deficiency syndrome mutations in heterologous Cells. *J. Biol. Chem.* 2016, 291, 22053–22062. [CrossRef] [PubMed]

91. Grubb, B.R.; Gabriel, S.E.; Mengos, A.; Gentzsch, M.; Randell, S.H.; Van Heeckeren, A.M.; Knowles, M.R.; Drumm, M.L.; Riordan, J.R.; Boucher, R.C. SERCA pump inhibitors do not correct biosynthetic arrest of ΔF508-cystic fibrosis transmembrane regulator and suppresses interleukin-8 levels: Therapeutic implications. *J. Biol. Chem.* 2002, 276, 17369–17378. [CrossRef] [PubMed]

90. Bertin, B.; Freissmuth, M.; Breyer, R.M.; Schütz, W.; Strosberg, A.D.; Marullo, S. Functional expression of two human serotonin 5-HT1A receptor in *Escherichia coli*. *Proc. Natl. Acad. Sci. USA* 1991, 88, 8548–8552. [CrossRef] [PubMed]

89. Freissmuth, M.; Selzer, E.; Marullo, S.; Schütz, W.; Strosberg, A.D. Expression of two human β-adrenergic receptors in *Escherichia coli*: Functional interaction with two forms of the stimulatory G protein. *Proc. Natl. Acad. Sci. USA* 1991, 88, 8548–8552. [CrossRef] [PubMed]

88. Generoso, S.F.; Giustiniano, M.; La Regina, G.; Bottone, S.; Passacantilli, S.; Di Maro, S.; Cassese, H.; Bruno, A.; Mallardo, M.; Dentice, M.; et al. Pharmacological folding chaperones act as allosteric ligands of Frizzled4. *Nat. Chem. Biol.* 2015, 11, 280–286. [CrossRef] [PubMed]

87. Leu, J.I.; Pimkina, J.; Frank, A.; Murphy, M.E.; George, D.L. A small molecule inhibitor of inducible heat shock protein 70. *Mol. Cell* 2009, 36, 15–27. [CrossRef] [PubMed]
108. Schlecht, R.; Scholz, S.R.; Dahmen, H.; Wegener, A.; Sirrenberg, C.; Musil, D.; Bomke, J.; Eggenweiler, H.M.; Mayer, M.P.; Bukau, B. Functional analysis of Hsp70 inhibitors. *PLoS ONE* **2013**, *8*, e78443. [CrossRef]

109. Janovick, J.A.; Stewart, M.D.; Jacob, D.; Martin, L.D.; Deng, J.M.; Stewart, C.A.; Wang, Y.; Cornea, A.; Chavali, L.; Lopez, S.; et al. Restoration of testis function in hypogonadotropic hypogonadal mice harboring a misfolded GnRHR mutant by pharmacoperone drug therapy. *Proc. Natl. Acad. Sci. USA* **2013**, *110*, 21030–21035. [CrossRef] [PubMed]